Report for: Ivermectin for onchocercal eye disease (river blindness)

Title	Ivermectin for onchocercal eye disease (river blindness)
Published in	Cochrane database of systematic reviews, August 2012
DOI	10.1002/14651858.cd002219.pub2
Pubmed ID	22895928
Authors	Henry OD Ejere, Ellen Schwartz, Richard Wormald, Jennifer R Evans
Abstract	It is believed that ivermectin (a microfilaricide) could prevent blindness due to onchocerciasis. However, when given to everyone in communities where onchocerciasis is common, the effects of ivermectin on lesions affecting the eye are uncertain and data on whether the drug prevents visual loss are unclear.

View on publisher site Alert me about new mentions

Twitter Demographics

The data shown below were collected from the profiles of 23 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Geographical breakdown

Country	Count	As %
France	4	17%
United States	4	17%
Unknown	15	65%

Demographic breakdown

Type	Count	As %
Members of the public	22	96%
Practitioners (doctors, other healthcare professionals)	1	4%

Mendeley readers

The data shown below were compiled from readership statistics for 120 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country	Count	As %
United Kingdom	2	2%
Brazil	1	<1%
Unknown	117	98%

Demographic breakdown

Readers by professional status	Count	As %
Researcher	19	16%
Student > Master	16	13%
Student > Bachelor	16	13%
Student > Ph. D. Student	11	9%
Student > Postgraduate	9	8%
Other	17	14%
Unknown	32	27%

Readers by discipline	Count	As %
Medicine and Dentistry	41	34%
Social Sciences	9	8%
Nursing and Health Professions	7	6%
Agricultural and Biological Sciences	7	6%
Psychology	5	4%
Other	19	16%
Unknown	32	27%

Attention Score in Context

This research output has an Altmetric Attention Score of 27. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 January 2023.

All research outputs

#1,257,877

of 23,164,913 outputs

Outputs from Cochrane database of systematic reviews

#2,881

of 12,383 outputs

Outputs of similar age

#7,513

of 168,405 outputs

Outputs of similar age from Cochrane database of systematic reviews

#43

of 207 outputs

Altmetric has tracked 23,164,913 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.

So far Altmetric has tracked 12,383 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 32.5. This one has done well, scoring higher than 76% of its peers.

Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 168,405 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.

We're also able to compare this research output to 207 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.

Cochrane Database of Systematic Reviews

Ivermectin for onchocercal eye disease (river blindness)

About this Attention Score

Mentioned by

Citations

Readers on

Twitter Demographics

Geographical breakdown

Demographic breakdown

Mendeley readers

Geographical breakdown

Demographic breakdown

Attention Score in Context